REGIME: A Randomised Controlled Trial of Prolonged Treatment With Darbepoetin Alpha, With or Without Recombinant Human Granulocyte Colony Stimulating Factor, Versus Best Supportive Care in Patients With Low-risk Myelodysplastic Syndromes (MDS).

Trial Profile

REGIME: A Randomised Controlled Trial of Prolonged Treatment With Darbepoetin Alpha, With or Without Recombinant Human Granulocyte Colony Stimulating Factor, Versus Best Supportive Care in Patients With Low-risk Myelodysplastic Syndromes (MDS).

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Darbepoetin alfa (Primary) ; Filgrastim
  • Indications Myelodysplastic syndromes; Refractory anaemia
  • Focus Biomarker; Therapeutic Use
  • Acronyms REGIME
  • Most Recent Events

    • 14 Mar 2012 Additional lead trial centres added as reported by ClinicalTrials.gov.
    • 02 Dec 2011 Status changed from not yet recruiting to recruiting as reported by ISRCTN: Current Controlled Trials.
    • 16 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top